Combining BCL-2 inhibitor venetoclax with monoclonal CD20 antibody rituximab greatly enhances progression-free survival compared with bendamustine-rituximab in a phase 3 trial of relapsed or refractory chronic lymphocytic leukemia patients.

中文翻译：

---

以“决斗”为目标的抗击白血病

与苯达莫司汀-利妥昔单抗的复发或难治性慢性淋巴细胞白血病患者的3期试验相比，将BCL-2抑制剂venetoclax与单克隆CD20抗体利妥昔单抗联合使用可大大提高无进展生存期。